NICE(UK): Trastuzumab deruxtecan can be used, within its marketing authorisation, as an option to treat HER2-low metastatic or unresectable breast cancer in adults after: i) chemotherapy in the… read more.
Many patients with early-stage breast cancer do not consistently maintain the long-term hormone therapy prescribed after lumpectomy, a large U.S. insurance claims analysis indicates. Findings provide important real-world… read more.
A short course of ultra-low-dose radiation therapy relieved painful bone lesions from multiple myeloma for most patients in a multi-institutional phase 2 clinical trial. The findings suggest that… read more.
Novocure announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Optune Pax for the treatment of adult patients diagnosed with unresectable locally advanced pancreatic cancer, concomitant… read more.
The National Institute for Health and Care Excellence (NICE) has issued four Technology Appraisal decisions in September 2026, comprising three positive first recommendations and one negative decision. Decisions… read more.
There is a pressing need to optimize medication strategies in older adults with cancer, many of whom take ≥5 medications. A randomized controlled trial published in the Journal… read more.
Merck, known as MSD outside of the United States and Canada, and Eisai announced the FDA has approved the dual oral regimen of WELIREG (belzutifan), Merck’s first-in-class oral… read more.
AbbVie announced today that new data from its broad multiple myeloma research portfolio will be featured at the 23rd International Myeloma Society (IMS) Annual Meeting, taking place September… read more.
Lantheus Holdings announced that the FDA has granted final approval for Bravnetsa (lutetium Lu 177 dotatate), a bioequivalent and therapeutically equivalent radiopharmaceutical to Lutathera (lutetium Lu 177 dotatate)…. read more.
Differences in how palliative care and oncology teams work together may help explain variation in end-of-life outcomes for patients with cancer, according to a multicentre qualitative study published… read more.
31 August 2026 – BeOne Medicines Ltd. announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera (zanidatamab), in combination… read more.
BeOne Medicines Ltd. announced that the FDA has approved the supplemental Biologics License Application (sBLA) for Tevimbra (tislelizumab) in combination with Ziihera (zanidatamab) and chemotherapy for the first-line… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
